N-acetylglycine N',N'-dimethylamide | 29824-30-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-acetylglycine N',N'-dimethylamide
• 英文别名: N-acetylglycine-N',N'-dimethylamide；Ac-Gly-N(Me)₂；2-acetylamino-N,N-dimethylacetamide；N-Acetyl-glycin-dimethylamid；N-Acetylglycin-dimethylamid；2-acetamido-N,N-dimethylacetamide
• CAS: 29824-30-4
• 化学式: C₆H₁₂N₂O₂
• mdl: MFCD19159613
• 分子量: 144.173
• InChiKey: ZRVISOPSRUBVQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-acetylglycine N',N'-dimethylamide 在 三乙胺 、 二溴三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以65%的产率得到N,N,2-三甲基-1,3-恶唑-5-胺
  参考文献：
  名称：

  An Efficient Synthesis ofN,N-Disubstituted 5-Aminooxazoles

  摘要：

  N,N-二取代的5-氨基噁唑，包括4-未取代的衍生物，通过一种新颖、便捷且高效的单锅法工艺，从相应的α-酰氨基酰胺出发，在回流二氯甲烷中使用二溴三苯基膦和三乙胺处理制备得到。

  DOI：

  10.1055/s-1992-26270
• 作为产物：
  描述：

  二甲胺 、 N-乙酰甘氨酸 在 N,N'-二环己基碳二亚胺 作用下， 生成 N-acetylglycine N',N'-dimethylamide
  参考文献：
  名称：

  An Efficient Synthesis ofN,N-Disubstituted 5-Aminooxazoles

  摘要：

  N,N-二取代的5-氨基噁唑，包括4-未取代的衍生物，通过一种新颖、便捷且高效的单锅法工艺，从相应的α-酰氨基酰胺出发，在回流二氯甲烷中使用二溴三苯基膦和三乙胺处理制备得到。

  DOI：

  10.1055/s-1992-26270

文献信息

• Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
  申请人：Kudo Yukitsuka

  公开号：US20060018825A1

  公开（公告）日：2006-01-26

  The present invention provides compounds having high affinity for amyloid β-protein which are for the diagnosis of diseases in which amyloid β-protein accumulates, for agents for specifically staining amyloid β-protein, and for the treatment and/or prophylaxis of diseases in which amyloid β-protein accumulates. The present invention also provides probes and staining agents for neurofibrillary tangles.

  本发明提供了对淀粉样蛋白β具有高亲和力的化合物，用于诊断淀粉样蛋白β在其中积累的疾病，用于特异染色淀粉样蛋白β的试剂，以及用于治疗和/或预防淀粉样蛋白β在其中积累的疾病。本发明还提供了用于神经原纤维缠结的探针和染色试剂。
• Raf inhibitor compounds and methods of use thereof
  申请人：Miknis Greg

  公开号：US20070049603A1

  公开（公告）日：2007-03-01

  Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物对抑制Raf激酶和治疗由此介导的疾病有用。公开了使用公式I的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Regioselective chelation in the reaction of N-trimethylsilyl-N-acetylglycine N’,N’-dimethylamide with chloro(chloromethyl)dimethylsilane
  作者：Sergey Yu. Bylikin、Alexander A. Korlyukov、Alexander G. Shipov、Dmitry E. Arkhipov、Natalia A. Kalashnikova、Vadim V. Negrebetsky、Yuri I. Baukov

  DOI：10.1016/j.mencom.2015.03.011

  日期：2015.3

  Regioselective reaction of N-trimethylsilyl-N-acetylglycine N’,N’-dimethylamide with chloro(chloromethyl)dimethylsilane yields chlorosilane MeC(O)N(CH2SiMe2Cl)CH2C(O)NMe2 with a five-membered C,O-chelate ring involving the N-acetyl group rather than the six-membered ring involving the N’,N’-dimethylamide fragment. According to X-ray data, the pentacoordinate silicon atom in the product has a TBP environment

  N-三甲基甲硅烷基-N-乙酰基甘氨酸N'，N'-二甲基酰胺与氯（氯甲基）二甲基硅烷的区域选择性反应产生具有五元C，O-螯合环的氯硅烷MeC（O）N（CH2SiMe2Cl）CH2C（O）NMe2 N-乙酰基而不是涉及N'，N'-二甲基酰胺片段的六元环。根据X射线数据，产物中的五配位硅原子具有TBP环境，其中卤素和氧原子位于轴向位置。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。
• Inhibitors of phosphatidylinositol 3-kinase
  申请人：Bruce Ian

  公开号：US20070032487A1

  公开（公告）日：2007-02-08

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物以自由或盐形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。